Drugs / ALXN1103
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01335165 | Apr 2011 → Mar 2014 | paroxysmal nocturnal hemoglobinuria | Alexion Pharmaceuticals, Inc. | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALXN1103 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01335165 ↗ |
| Known as | TT30 | “single dose of TT30 (ALXN1102 and ALXN1103 formulations)” NCT01335165 ↗ |
| Route | Intravenous | “Single Ascending Dose IV or SC” NCT01335165 ↗ |
| Route | Subcutaneous | “Single Ascending Dose IV or SC” NCT01335165 ↗ |